TherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer

TherapeuticsMD (NASDAQ:TXMD)‘s stock had its “buy” rating reissued by research analysts at Oppenheimer in a report issued on Sunday. They presently have a $10.00 target price on the stock. Oppenheimer’s price objective would suggest a potential upside of 56.49% from the stock’s previous close.

Several other equities analysts also recently commented on TXMD. BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Friday, October 13th. Cowen reissued an “outperform” rating and issued a $16.00 price objective (up previously from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 price objective on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Finally, Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, December 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $14.50.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.07 during trading hours on Friday, reaching $6.39. 670,164 shares of the company traded hands, compared to its average volume of 1,631,937. The company has a market cap of $1,397.94, a P/E ratio of -15.97 and a beta of 1.36. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm’s revenue was down 19.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) EPS. equities research analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the purchase, the director now owns 3,555 shares of the company’s stock, valued at $22,076.55. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 23.92% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in TXMD. Schwab Charles Investment Management Inc. raised its stake in shares of TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after acquiring an additional 67,855 shares during the last quarter. Legal & General Group Plc raised its stake in shares of TherapeuticsMD by 6.5% during the second quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock valued at $298,000 after acquiring an additional 3,441 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after acquiring an additional 818 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of TherapeuticsMD by 10.8% during the second quarter. Alliancebernstein L.P. now owns 254,240 shares of the company’s stock valued at $1,340,000 after acquiring an additional 24,700 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of TherapeuticsMD by 5.0% during the second quarter. Teachers Advisors LLC now owns 671,445 shares of the company’s stock valued at $3,539,000 after acquiring an additional 31,843 shares during the last quarter. 73.86% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “TherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/29/therapeuticsmd-txmd-rating-reiterated-by-oppenheimer.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply